Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 4 1Phase 1/2 1

Status

Completed 59Terminated 10Unknown 7Active not recruiting 5Withdrawn 4Recruiting 4No longer available 3Not yet recruiting 1Approved for marketing 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 4Myeloid 4

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Neoplasms 2Neoplasm Metastasis 2Leukemia, Myeloid, Chronic-Phase 2Ovarian Neoplasms 1Myeloproliferative Disorders 1Melanoma 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Blast Crisis 1

Interventions

asciminib 10Cyclophosphamide 9Mycophenolic Acid 7fludarabine 5Whole-Body Irradiation 5nilotinib 4fludarabine phosphate 4Stem Cell Transplantation 4Specimen Handling 4Dasatinib 4olverembatinib 3bosutinib 3Imatinib Mesylate 3Cyclosporine 3venetoclax 2ponatinib 2blinatumomab 2X-Rays 2Thiotepa 2Tacrolimus 2Sirolimus 2Melphalan 2Magnetic Resonance Spectroscopy 2Hematopoietic Stem Cell Transplantation 2Granulocyte Colony-Stimulating Factor 2Filgrastim 2Cyclosporins 2Bone Marrow Transplantation 2Blood Component Removal 2Biopsy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Recruiting × Leukemia, Myelogenous, Chronic, BCR-ABL Positive × nilotinib × Clear all
NCT04877522 2026-05-11

Asciminib Roll-over Study

Novartis

Phase 4 Recruiting
347 enrolled
MyeloidOther hematologic neoplasm

Blast Crisis, Myeloproliferative Disorders, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT04838041 2025-07-30

Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation

Medical College of Wisconsin

Phase 2 Recruiting
51 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT06409936 2025-07-08

PEARL

Gruppo Italiano Malattie EMatologiche dell'Adulto

Phase 2 Recruiting
160 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT04835584 2022-03-21

KRT-232 and TKI Study in Chronic Myeloid Leukemia

Kartos Therapeutics, Inc.

Phase 1/2 Recruiting
109 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡